The invention relates to transgenic non-human animals that express the AMPK ??3 subunit and methods of using the animals for the development of drugs for the treatment or prevention of diseases related to energy metabolism, such as obesity, dyslipidemia, insulin resistance syndrome, and type 2 diabetes.